Arbutus Biopharma Corp Insider Trading Arrangements
Rule 10b5-1 and other trading arrangements that directors and officers adopted or terminated, as each 10-Q and 10-K tags them (Item 408(a)), newest report first.
- 2025-05-14: Arrangement Rule 10b5-1; Adopted March 28, 2025.
- 2024-11-06: Arrangement Rule 10b5-1; Adopted September 18, 2024.
- 2024-11-06: Individual Michael J. Sofia.
| Report filed | Individual | Title | Arrangement | Adopted | Terminated | Expires or duration | Securities covered |
|---|---|---|---|---|---|---|---|
| 2025-05-14 10-Q | Rule 10b5-1 | March 28, 2025 | |||||
| 2024-11-06 10-Q | Rule 10b5-1 | September 18, 2024 | April 15, 2025 | 96,456 | |||
| 2024-11-06 10-Q | Michael J. Sofia |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |